Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01830426
Official study title

Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

Study summary

The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 22, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?Epic Sciences

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Epic Sciences
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Suspected lung cancer
  • Planned to undergo tissue biopsy. Tissue biopsy does not need to be limited to an intrathoracic structures. Biopsies of the supraclavicular lymph nodes are allowed
  • Age \>18
Reasons someone may not be able to joinExclusion criteria
  • Patients with history of a separate (not a primary lung cancer) malignancy within past two years.
  • Recent history (past two weeks) of trauma (INCLUDING diagnostic surgery, biopsy, etc)
  • Prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years.
  • Inability to provide informed consent.
  • Hgb less than 8.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Moores Cancer CenterLa Jolla, California
  • Yale UniversityNew Haven, Connecticut
  • Billings Clinic Cancer CenterBillings, Montana

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 22, 2016. Always confirm current availability with the study team.

View original record ↗